% | $
Quotes you view appear here for quick access.

Neostem, Inc. Message Board

  • hwmccusker hwmccusker Feb 11, 2013 8:39 AM Flag

    Potter to BOD

    The Bottom Line: Stephen Potter’s “hands-on” years and track record of launching products, formulating, implementing business strategies, executing high value transactions will provide key insights and meaningful guidance to NBS. For disclosure purposes, Steve is a personal friend; I expect this board role to generate some “BUZZ” as … few companies have Steve’s cell therapy knowledge and standing … In this particular case – it should be worth …+$0.02-$0.03 … to the share value, GENZ and OSIR have been on the cutting edge of cell therapy and he was the driver of product development and market launch in both cases! Look for a broadening outlook of NBS’ reach in the cell therapy universe!
    NBS closed at $0.65, down $0.01 on 2/8/13.

    Sentiment: Buy

2.250.00(0.00%)Jun 5 3:59 PMEDT